Abstracts tagged "anti-citrullinated protein/peptide antibodies (ACPA)"

Abstract Number: 2138 • 2014 ACR/ARHP Annual Meeting
Radiological Outcomes after Two Years of Remission Steered Treatment in Early Arthritis Patients
G. Akdemir¹, L. Heimans¹, K.V.C. Wevers-de Boer¹, M.K. Verheul², A.a. Schouffoer³, M. van Oosterhout⁴, J.B. Harbers⁵, C. Bijkerk⁶, G.M. Steup-Beekman⁷, L.R. Lard⁸, T. W. J. Huizinga¹, L.a. Trouw¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Rheumatology, GHZ Hospital, Gouda, Netherlands, ⁵Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, ⁶Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁷Rheumatology, Bronovo Hospital, The Hague, Netherlands, ⁸Rheumatology, MCH Antoniushove Hospital, Leidschendam, Netherlands
Background/Purpose: We investigated whether early, remission steered treatment can prevent damage progression in patients with early rheumatoid arthritis (RA) or undifferentiated arthritis (UA), and aimed…
Abstract Number: 1470 • 2014 ACR/ARHP Annual Meeting
Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti-Malondialdehyde-Acetaldehyde Antibody in Rheumatoid Arthritis
Geoffrey Thiele¹, Michael J. Duryee², Daniel Anderson³, Lynell W. Klassen⁴, Stephen Mohring⁵, Kathleen Young⁶, Dathe Benissan-Messan⁷, Harlan Sayles³, Jeremy Sokolove⁸, William H. Robinson⁹, James O' Dell³, Anthony Nicholas¹⁰ and Ted R. Mikuls³, ¹Int Med/Sec of Rheum/Immun, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁶Int Med/Sec of Rheum/Immun, University of Nebraska Medical Center, Omaha, NE, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁹VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ¹⁰Neurology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Products of oxidative stress, MAA adducts are highly immunogenic and have been associated with tolerance loss. To examine their potential role in disease-related…
Abstract Number: 451 • 2014 ACR/ARHP Annual Meeting
The Association of Fine Specificities of Anti-Citrullinated Protein Antibodies (ACPA) with disease Severity in African-Americans with RA
Maria I. Danila¹, Richard Reynolds², Gordon Wu³, Hemant Tiwari³, William H. Robinson⁴, Jeremy Sokolove⁵, CLEAR Investigators² and S. Louis Bridges Jr.^2,6, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: RA is characterized by the presence of autoantibodies to citrullinated proteins (ACPA) and joint damage. The role of fine specificities of ACPA in radiographic…
Abstract Number: 2406 • 2013 ACR/ARHP Annual Meeting
The Relationship Between Anti-Citrullinated Protein Antibodies and Radiographic Damage In African-Americans With Rheumatoid Arthritis
Maria I. Danila¹, Richard J. Reynolds², Stella Aslibekyan³, Ashutosh Tamhane³, Laura B. Hughes⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Doyt L. Conn⁷, Beth L. Jonas⁸, Leigh F. Callahan⁹, Larry W. Moreland¹⁰, Richard D. Brasington¹¹, Edwin A. Smith¹², Ted R. Mikuls¹³, Désirée van der Heijde¹⁴ and S. Louis Bridges Jr.¹⁵, ¹Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Med Div of Clin Imm & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁷Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ⁸Thurston Arthritis Research Ct, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁹Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC, ¹⁰Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ¹²Dept of Med Div of Rheum, Med Univ of South Carolina, Charleston, SC, ¹³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Joint erosions and joint space narrowing may lead to impaired functional status and disability in rheumatoid arthritis (RA). Autoantibodies to citrullinated proteins (ACPA) are present in…
Abstract Number: 2264 • 2013 ACR/ARHP Annual Meeting
An Assay Panel Combining Anticitrullinated Peptide Autoantibodies and Rheumatoid Factor Isotypes Has High Yield In The Diagnosis Of Rheumatoid Arthritis
Nirupa J. Patel¹, Ignacio Garcia-Valladares², Derren Barken³, Luis R. Espinoza⁴, Heena Sheth⁵ and Thierry Dervieux⁶, ¹Rheumatology, LSU Health Sciences Ctr, New Orleans, LA, ²Rheumatology, Guadalajara, Guadalajara, Mexico, ³Exagen Diagnostics, Vista, CA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁵Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: We sought to establish the diagnostic performances of rheumatoid factor isotypes (IgM and IgA) and anti-citrullinated peptide antibodies (ACPAs: anti-mutated citrullinated vimentin [anti-MCV] and…
Abstract Number: 1309 • 2013 ACR/ARHP Annual Meeting
Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis
Lillian J. Barra¹, Janet E. Pope², Boulos Haraoui³, Carol A. Hitchon⁴, J. Carter Thorne⁵, Edward C. Keystone^6,7, Diane Tin⁸, Gilles Boire⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ³Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) are believed to be associated with more severe clinical outcomes; however, studies in Early Inflammatory Arthritis…
Abstract Number: 1158 • 2013 ACR/ARHP Annual Meeting
Decreased NK-Cell Numbers and Upregulation Of Markers Of Systemic Inflammation In Autoantibody –Positive Arthralgia Patients and Early Rheumatoid Arthritis Patients But Not In Autoantibody-Negative Rheumatoid Arthritis Patients
Paulina Chalan¹, Johan Bijzet², Kornelis S.M. van der Geest¹, Bart-Jan Kroesen³, Annemieke M.H. Boots^4,5 and Elisabeth Brouwer¹, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Dept. of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Groningen Research initiative on healthy Ageing and Immune Longevity (GRAIL), Groningen, Netherlands
Background/Purpose: Identification of seropositive individuals at risk for arthritis development would open opportunities for early clinical intervention. In a recent study on seropositive arthalgia patients…
Abstract Number: 411 • 2012 ACR/ARHP Annual Meeting
Early Menopause, Smoking and Circulating Antibodies Against Citrullinated Peptides in the Pre-Clinical Phase of Rheumatoid Arthritis
Mitra Pikwer¹, Johan Rönnelid², Monika Hansson³, Ulf Bergström¹, Lennart T.H. Jacobsson⁴, Linda Mathsson², Per Johan Jakobsson⁵, Guy B. Serre⁶, Rikard Holmdahl⁷, Lars Klareskog⁸ and Carl Turesson⁴, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Laboratory of Epidermis differentiation and Rheumatoid autoimmunity, Centre National de la Recherche Scientifique - Université de Toulouse, Toulouse, France, ⁷Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Previous studies indicate that anti-citrullinated peptide antibodies (ACPAs) may be detected in individuals who later develop rheumatoid arthritis (RA) years before onset, and that…
Abstract Number: 414 • 2012 ACR/ARHP Annual Meeting
First-Degree Relatives without Rheumatoid Arthritis Exhibit Reactivity to Multiple Anti-Citrullinated Protein Antibodies in Association with Rheumatoid Arthritis-Related Clinical Characteristics: Studies of the Etiology of Rheumatoid Arthritis
Kendra A. Young¹, Kevin D. Deane², Lezlie A. Derber³, Jan M. Hughes-Austin⁴, Michael H. Weisman⁵, Jane H. Buckner⁶, Ted R. Mikuls⁷, James R. O'Dell⁸, Richard M. Keating⁹, Peter K. Gregersen¹⁰, V. Michael Holers¹¹ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, ⁴Epidemiology, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁹Rheumatology Section, The University of Chicago, Chicago, IL, ¹⁰Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ¹¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Prior to diagnosis of rheumatoid arthritis (RA), there are increases in the number of citrullinated proteins that anti-citrullinated protein antibodies (ACPA) target, suggesting an…
Abstract Number: 421 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not Antibodies to Citrullinated Proteins, Are Associated with High Disease Activity
Josef S. Smolen¹, Farideh Alasti² and Daniel Aletaha³, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Autoantibodies in general, and rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) in particular, are a hallmark of RA. After their characterization, ACPA have…
Abstract Number: 422 • 2012 ACR/ARHP Annual Meeting
Antibodies to Citrulline From Rheumatoid Arthritis Patients Also Bind Homocitrulline
Mathias Scinocca¹, Radha Joseph², David A. Bell³, Ewa Cairns³ and Lillian J. Barra³, ¹Microbiology and Immunology, Schulich School of Medicine and Dentistry, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ³Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: Antibodies to citrullinated proteins/peptides (ACPA) are specific for Rheumatoid Arthritis (RA). One of ACPA’s targets is citrullinated fibrinogen (citfib) and it is found in…
Abstract Number: 2576 • 2012 ACR/ARHP Annual Meeting
Production of Citrullinated Filaggrin-Specific IgG in Rheumatoid Arthritis Patients Is Associated with an Expansion of Citrullinated Filaggrin Tetramer-Binding Switched Memory Blood B Cells
Philip Titcombe¹, Laura O. Barsness¹, Lauren Giacobbe¹, Emily Baechler Gillespie¹, Erik J. Peterson² and Daniel L. Mueller², ¹University of Minnesota Medical School, Minneapolis, MN, ²Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: Rheumatoid Arthritis (RA) is highly associated with the production of autoantibodies, including rheumatoid factors and anti-citrullinated protein antibodies (ACPA). It remains uncertain whether production…
Abstract Number: 63 • 2012 ACR/ARHP Annual Meeting
The Association Between Silica and the Risk of Anti-Citrullinated Protein Antibody Positive RA in the Malaysian and Swedish Epidemiological Investigation of Rheumatoid Arthritis Studies
Abqariyah Yahya¹, Camilla Bengtsson¹, Lars Klareskog², Chun Lai Too³, Shahnaz Murad⁴ and Lars Alfredsson¹, ¹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Institute for Medical Research, Kuala Lumpur, Kuala Lumpur, Malaysia
Background/Purpose: Silica exposure has been associated with an increased risk of developing ACPA+ (anti-citrullinated protein antibody) RA, especially among smokers (1). These findings were based…
Abstract Number: 2581 • 2012 ACR/ARHP Annual Meeting
Anti- Citrullinated Protein Antibodies but Not Rheumatoid Factor Are Associated with Larger Bone Erosions in rheumatoid arthritis patients- a Cross-Sectional Micro Computed Tomography Study
Carolin Hecht¹, Stephanie Finzel¹, Matthias Englbrecht¹, Sarah Schmidt¹, Juergen Rech², Elizabeth Araujo¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti- citrullinated protein antibodies (ACPA) are known to be associated with joint destruction and a more severe disease course in rheumatoid arthritis (RA) patients.…
Abstract Number: 26 • 2012 ACR/ARHP Annual Meeting
Quantitative Analysis of Bone Damage Morphological Changes in the Citrullinated Collagen Induced Arthritis Mouse Model Using Micro CT
Anand Dusad¹, Michael J. Duryee², Dong Wang³, James R. O'Dell⁴, Ted R. Mikuls⁵, Geoffrey M. Thiele⁶ and Lynell W. Klassen⁴, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Pharmaceutical Sciences, Univ of Nebraska Medical Ctr, Omaha, NE, ⁴Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁶Int Med/Sec of Rheum/Immun, Univ of Nebraska Med Ctr, Omaha, NE
Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].